Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 18, 2017 - Issue 4
Submit an article Journal homepage
125
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Nebivolol can be used for combination therapy in patients with autosomal dominant polycystic kidney disease

Ismail KocyigitDepartment of Internal Medicine, Division of Nephrology, Erciyes University School of Medicine, Kayseri, TurkeyView further author information
,
Eray ErogluDepartment of Internal Medicine, Division of Nephrology, Erciyes University School of Medicine, Kayseri, TurkeyCorrespondence[email protected]
View further author information
&
Tevfik EcderDepartment of Internal Medicine, Division of Nephrology, Istanbul Bilim University School of Medicine, Istanbul, TurkeyView further author information
Page 455 | Received 01 Oct 2016, Accepted 07 Feb 2017, Published online: 17 Feb 2017

References

  • Rysz J, Gluba-Brzózka A, Franczyk B, et al. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Pharmacother. 2016;17(15):2049–2056.
  • Blair HA, Keating GM. Tolvaptan: a review in autosomal dominant polycystickidney disease. Drugs. 2015;75(15):1797–1806.
  • Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):153–163.
  • Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013;9:2–11.
  • Veverka A, Salinas JL. Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag. 2007;3(5):647–654.
  • Sander GE, Giles TD. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. Expert Opin Pharmacother. 2015;16(5):763–770.
  • Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491–1499.
  • Klawitter J, Reed-Gitomer BY, McFann K, et al. Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol. 2014;307(11):1198–1206.
  • Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383(9932):1889–1898.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.